ArriVent BioPharma Appoints Brent S. Rice as Chief Commercial Officer

ArriVent BioPharma, Inc. has appointed Brent S. Rice as its new Chief Commercial Officer, signaling a strategic move to bolster its commercial operations. Rice brings over 25 years of extensive experience in the biotechnology and pharmaceutical sectors, having previously served as Senior Vice President and Global Chief Commercial Officer at Autolus Therapeutics Ltd.. During his tenure there, he played a key role in establishing the U.S. organization and successfully launching its inaugural commercial product.

Rice’s career includes notable leadership positions at Juno Therapeutics and nearly two decades at Amgen, where he was instrumental in developing payer strategies, reimbursement protocols, and product launches across various therapeutic areas. His proven track record in launching innovative therapies and building high-performing teams makes him a valuable addition to ArriVent as it prepares for significant regulatory milestones.

Strategic Vision and Leadership

Bing Yao, Chairman and CEO of ArriVent, emphasized the importance of Rice’s appointment in a statement. “Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning,” Yao said. He expressed confidence that Rice’s executive leadership experience will be crucial as the company moves closer to potential approval and commercialization of firmonertinib for treating EGFR mutant non-small cell lung cancer.

Rice himself expressed enthusiasm about his new role. “The company has a robust, science-driven pipeline that targets challenging and underserved areas in oncology,” he commented. He looks forward to collaborating with the team to drive growth and ensure that patients have access to these promising innovations.

Preparing for Commercialization

Rice’s appointment arrives at a critical juncture for ArriVent as it gears up for potential regulatory approvals and transitions toward full commercialization. The company is focused on unlocking the potential of its Antibody-Drug Conjugate (ADC) portfolio while navigating the complexities of the biotechnology landscape.

As ArriVent BioPharma continues to make strides in its mission, the leadership of Brent S. Rice is expected to play a pivotal role in shaping the company’s future. The emphasis on a strong commercial foundation aligns with the company’s goals of addressing unmet medical needs and enhancing patient access to groundbreaking therapies.